Prothena Corp Public Ltd Co (PRTA) stock
PRTANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3017% below fair value
$8.16−0.07 (-0.85%)
Close on Nov 13, 2026Market cap $418.91MP/E –Yield –
Earnings
Prothena Corp Public's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Feb 18, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$600.00K
-75.0% on a year earlier
EPS, Q3 FY2026
-$0.32
-$0.68 a year earlier
Latest guidance
Raised
Nov 5, 2026 · 4 items
Quarterly results
Revenue and earnings per share from each of Prothena Corp Public's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 18, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026after the close | $600.00K | -75.0% | -$0.32 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 6, 2026after the close | $1.00M | -77.3% | -$0.36 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026after the close | $51.10M | +1725.0% | $0.60 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 19, 2026after the close | $21.00K | -99.0% | -$0.40 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025after the close | $2.40M | +140.0% | -$0.68 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 4, 2025after the close | $4.40M | -96.7% | -$2.34 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025after the close | $2.80M | +2700.0% | -$1.12 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 20, 2025after the close | $2.10M | +600.0% | -$1.08 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 12, 2024after the close | $1.00M | -98.8% | -$1.10 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 8, 2024after the close | $132.00M | +3200.0% | $1.22 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 8, 2024after the close | $100.00K | -95.5% | -$1.34 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 15, 2024after the close | $300.00K | -99.4% | -$1.26 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023after the close | $84.90M | +5560.0% | $0.38 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023after the close | $4.00M | +207.7% | -$1.03 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023after the close | $2.20M | +83.3% | -$0.89 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 23, 2023after the close | $49.90M | +4058.3% | $0.12 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022after the close | $1.50M | -98.9% | -$0.97 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 8, 2022after the close | $1.30M | – | -$0.88 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 5, 2022after the close | $1.20M | – | -$0.78 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 17, 2022after the close | $1.20M | – | -$0.71 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021after the close | $139.20M | – | $2.13 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021after the close | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 11, 2021after the close | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 11, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 4, 2020after the close | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Prothena Corp Public's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| cash | FY2026 | $255.00M | – | Raised | Feb 19, 2026 |
| cash, cash equivalents and restricted cash | FY2026 | $259.00M | – | Raised | Nov 5, 2026 |
| cash, cash equivalents and restricted cash | FY2026 | $259.00M | $273.00M | Raised | Aug 6, 2026 |
| net cash used in operating and investing actives | FY2026 | $18.00M – $23.00M | – | Lowered | May 7, 2026 |
| net cash used in operating and investing activities | FY2026 | $18.00M – $23.00M | – | New | Nov 5, 2026 |
| net cash used in operating and investing activities | FY2026 | $18.00M – $23.00M | $50.00M – $55.00M | Lowered | Aug 6, 2026 |
| net loss | FY2026 | $25.00M – $30.00M | – | Lowered | Nov 5, 2026 |
| net loss | FY2026 | $25.00M – $30.00M | -$72.00M – -$67.00M | Lowered | Aug 6, 2026 |
| net lossGAAP | FY2026 | -$30.00M – -$25.00M | – | New | May 7, 2026 |
| non-cash share-based compensation expense | FY2026 | $26.00M | – | Narrowed | Nov 5, 2026 |
| non-cash share-based compensation expense | FY2026 | $26.00M | $24.00M | Lowered | May 7, 2026 |
Guidance history
Every forecast Prothena Corp Public put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 5, 2026 | net cash used in operating and investing activities | FY2026 | $18.00M – $23.00M | New |
| Nov 5, 2026 | cash, cash equivalents and restricted cash | FY2026 | $259.00M | Raised |
| Nov 5, 2026 | net loss | FY2026 | $25.00M – $30.00M | Lowered |
| Nov 5, 2026 | non-cash share-based compensation expense | FY2026 | $26.00M | Narrowed |
| Aug 6, 2026 | net cash used in operating and investing activities | FY2026 | $18.00M – $23.00M | Lowered |
| Aug 6, 2026 | cash, cash equivalents and restricted cash | FY2026 | $259.00M | Raised |
| Aug 6, 2026 | net loss | FY2026 | $25.00M – $30.00M | Lowered |
| May 7, 2026 | net cash used in operating and investing actives | FY2026 | $18.00M – $23.00M | Lowered |
| May 7, 2026 | cash, cash equivalents and restricted cash | FY2026 | $273.00M | Raised |
| May 7, 2026 | non-cash share-based compensation expense | FY2026 | $26.00M | Lowered |
| May 7, 2026 | net loss | FY2026 | -$30.00M – -$25.00M | New |
| Feb 19, 2026 | net cash used in operating and investing activities | FY2026 | $50.00M – $55.00M | New |
| Feb 19, 2026 | cash | FY2026 | $255.00M | Raised |
| Feb 19, 2026 | net loss | FY2026 | -$72.00M – -$67.00M | Lowered |
| Feb 19, 2026 | non-cash share-based compensation expense | FY2026 | $24.00M | Raised |
| Nov 6, 2025 | net cash used in operating and investing activities | FY2025 | $170.00M – $178.00M | New |
| Nov 6, 2025 | cash, cash equivalents, and restricted cash | FY2025 | $298.00M | Raised |
| Nov 6, 2025 | net loss | FY2025 | -$248.00M – -$240.00M | Lowered |
| Aug 4, 2025 | net cash used in operating and investing activities | FY2025 | $170.00M – $178.00M | Raised |
| Aug 4, 2025 | cash, cash equivalents, and restricted cash | FY2025 | $298.00M | Raised |
| Aug 4, 2025 | net loss | FY2025 | -$248.00M – -$240.00M | Lowered |
| Feb 20, 2025 | net cash used in operating and investing activities | FY2025 | $168.00M – $175.00M | New |
| Feb 20, 2025 | cash, cash equivalents and restricted cash | FY2025 | $301.00M | Raised |
| Feb 20, 2025 | net loss | FY2025 | $197.00M – $205.00M | Lowered |
| Feb 20, 2025 | non-cash share-based compensation expense | FY2025 | $41.00M | Lowered |
| Nov 12, 2024 | net cash used in operating and investing actives | FY2024 | $148.00M – $160.00M | Raised |
| Nov 12, 2024 | cash, cash equivalents and restricted cash | FY2024 | $468.00M | Raised |
| Nov 12, 2024 | net loss | FY2024 | $120.00M – $135.00M | Lowered |
| Nov 12, 2024 | non-cash share-based compensation expense | FY2024 | $48.00M | Lowered |
| Aug 8, 2024 | net cash used in operating and investing actives | FY2024 | $148.00M – $160.00M | Raised |
| Aug 8, 2024 | cash, cash equivalents and restricted cash | FY2024 | $468.00M | Raised |
| Aug 8, 2024 | net loss | FY2024 | $120.00M – $135.00M | Lowered |
| Aug 8, 2024 | non-cash share-based compensation expense | FY2024 | $48.00M | Lowered |
| May 8, 2024 | net cash used in operating and investing activities | FY2024 | $208.00M – $225.00M | Raised |
| May 8, 2024 | cash, cash equivalents and restricted cash | FY2024 | $405.00M | Raised |
| May 8, 2024 | net loss | FY2024 | $229.00M – $255.00M | Lowered |
| May 8, 2024 | non-cash share-based compensation expense | FY2024 | $51.00M | Lowered |
| Feb 15, 2024 | net cash used in operating and investing activities | FY2024 | $208.00M – $225.00M | New |
| Feb 15, 2024 | cash, cash equivalents and restricted cash | FY2024 | $405.00M | Raised |
| Feb 15, 2024 | non-cash share-based compensation expense | FY2024 | $51.00M | Lowered |
| Feb 15, 2024 | net loss | FY2024 | $229.00M – $255.00M | New |
| Aug 3, 2023 | net cash burn from operating and investing activities | FY2023 | $148.00M – $161.00M | Raised |
| Aug 3, 2023 | cash, cash equivalents and restricted cash | FY2023 | $600.00M | Raised |
| Aug 3, 2023 | non-cash share-based compensation expense | FY2023 | $42.00M | Lowered |
| Aug 3, 2023 | net loss | FY2023 | $153.00M – $171.00M | New |
| May 4, 2023 | net cash used in operating and investing activities | FY2023 | $213.00M – $229.00M | Raised |
| May 4, 2023 | cash, cash equivalents and restricted cash | FY2023 | $512.00M | Raised |
| May 4, 2023 | net loss | FY2023 | $250.00M – $275.00M | Lowered |
| May 4, 2023 | non-cash share-based compensation expense | FY2023 | $46.00M | Lowered |
| Feb 23, 2023 | net cash used in operating and investing activities | FY2023 | $213.00M – $229.00M | New |
| Feb 23, 2023 | cash, cash equivalents and restricted cash | FY2023 | $512.00M | Raised |
| Feb 23, 2023 | net loss | FY2023 | $250.00M – $275.00M | Lowered |
| Feb 23, 2023 | non-cash share-based compensation expense | FY2023 | $46.00M | Lowered |
| Nov 3, 2022 | net cash burn from operating and investing activities | FY2022 | $108.00M – $120.00M | Lowered |
| Nov 3, 2022 | cash, cash equivalents, and restricted cash | FY2022 | $522.00M | Raised |
| Nov 3, 2022 | net loss | FY2022 | $121.00M – $137.00M | Lowered |
| Aug 8, 2022 | net cash used in operating and investing activities | FY2022 | $120.00M – $132.00M | Lowered |
| Aug 8, 2022 | cash, cash equivalents and restricted cash | FY2022 | $454.00M | Raised |
| Aug 8, 2022 | net loss | FY2022 | $154.00M – $170.00M | Lowered |
| May 5, 2022 | net cash used in operating and investing activities | FY2022 | $120.00M – $132.00M | Raised |
| May 5, 2022 | cash, cash equivalents and restricted cash | FY2022 | $454.00M | Raised |
| May 5, 2022 | net loss | FY2022 | $154.00M – $170.00M | Lowered |
| Feb 17, 2022 | net cash used in operating and investing activities | FY2022 | $120.00M – $132.00M | New |
| Feb 17, 2022 | clinical milestone payment | FY2022 | $40.00M | Lowered |
| Feb 17, 2022 | cash, cash equivalents and restricted cash | FY2022 | $454.00M | Raised |
| Feb 17, 2022 | net loss | FY2022 | $154.00M – $170.00M | Lowered |
| Feb 17, 2022 | non-cash share-based compensation expense | FY2022 | $32.00M | Lowered |
| Nov 4, 2021 | net cash provided by operating and investing activities | FY2021 | $85.00M – $95.00M | New |
| Nov 4, 2021 | projected year end cash balance | FY2021 | $575.00M | Raised |
| Nov 4, 2021 | net income | FY2021 | $50.00M – $60.00M | Lowered |
| Nov 4, 2021 | non-cash share-based compensation expense | FY2021 | $25.00M | Lowered |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Prothena Corp Public filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- Results
- Results
- News
- News
- Results
- News
- News
- Results
- Results
- Results
- Update
See a number that looks wrong?